Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA V ‘Program’ Gets Positive Evaluation – Except For Inspections

This article was originally published in The Pink Sheet Daily

Executive Summary

Longer application review time has been producing the improved communication sponsors expected, but modifications to the user fee program have yet to make inspections go smoother.

You may also be interested in...



US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators

Leveraging foreign surveillance inspections could help FDA ensure more sites are inspected more often.

Sponsor-FDA Communications In IND Phase Will Get Outside Review

US FDA seeks White House approval for to contract for interviews with 100 to 150 active commercial IND holders.

Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?

Final assessment of the PDUFA V new drug review 'Program' flagged inspection delays as a continued sticking point for on-time approvals. US FDA says consolidation of manufacturing oversight under the agency’s new quality office will help.

Related Content

Topics

UsernamePublicRestriction

Register

PS078358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel